Memo Therapeutics

Series-B+
memo-therapeutics.com Biotech & Healthcare
Total Funding $27.0M
Latest Round $22M Series-B+
Last Announced May 7, 2024
Investors Undisclosed
Decision Makers 3 Verified

About Memo Therapeutics

Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website memo-therapeutics.com
Domain Registered Date Nov 11, 2012

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $22,000,000 · Series-B+

    startupintros.com

  2. Capital Raise

    Raised $4,990,000 · Series-A

    startupintros.com

  3. Milestone

    Website domain registered

    memo-therapeutics.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Memo Therapeutics.

Funding History

2 Rounds
Series-B+ · May 7, 2024
Series-A · May 9, 2018

Founders & Leadership

1

Christoph Esslinger

Co-founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts